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Abstract Previous studies showed that bone marrow-
derived mesenchymal stem cells (BMSCs) could amelio-
rate a variety of immune-mediated and inflammatory dis-
eases due to their immunomodulatory and anti-
inflammatory effects. In this study, we developed a mouse
model of ovalbumin (OVA) induced allergic inflammation
in the upper airways and evaluated the effects of the
intraperitoneal administration of BMSCs on allergic
inflammation. Twenty-five BALB/c mice were divided into
five groups; group I (control group), group II (sensitized
and challenged with OVA and treated with saline-placebo
group), group III (sensitized and challenged with OVA and
treated with 1 9 106 BMSCs), group IV (sensitized and
challenged with OVA and treated with 2 9 106 BMSCs),
and group V (sensitized and challenged with phosphate
buffered saline (PBS) and treated with 1 9 106 BMSCs).
Histopathological features (number of goblet cells, eosi-
nophils and mast cells, basement membrane, epithelium
thickness, and subepithelial smooth muscle thickness) of
the upper and lower airways and BMSCs migration to nasal
and lung tissue were evaluated using light and confocal
microscopes. Levels of cytokines in the nasal lavage fluid
and lung tissue supernatants were measured using enzyme-
linked immunosorbent assay (ELISA). Confocal micro-
scopic analysis showed that there was no significant
amount of BMSCs in the nasal and lung tissues of group V.
However, significant amount of BMSCs were observed in
group III and IV. In OVA-induced AR groups (group II, III,
and IV), histopathological findings of chronic asthma, such
as elevated subepithelial smooth muscle thickness,
epithelium thickness, and number of goblet and mast cells,
were determined. Furthermore, the number of nasal goblet
and eosinophil cells, histopathological findings of chronic
asthma, and IL-4, IL-5, IL-13, and NO levels was signifi-
cantly lower in both BMSCs-treated groups compared to
the placebo group. Our findings indicated that histopatho-
logical findings of chronic asthma were also observed in
mice upon AR induction. BMSCs migrated to the nasal and
lung tissues following intraperitoneal delivery and ame-
liorated to the airway remodeling and airway inflammation
both in the upper and lower airways via the inhibition of T
helper (Th) 2 immune response in the murine model of AR.
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Introduction
Allergic rhinitis (AR) is a common chronic disease char-
acterized by the symptoms of sneezing, rhinorrhea, itchi-
ness, and nasal congestion. AR is a global health problem
affecting 10–30 % of adults and 20–40 % of children [1].
Patients with AR show an inflammatory IgE-mediated
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response characterized by Th2 immunological pattern
together with mast cells, goblet cells, and eosinophil acti-
vation, as well as the release of inflammatory mediators,
such as IL-4, IL-5, and IL-13, against allergen exposure
[2]. Multiple treatment options, including medical treat-
ment, immunotherapy, intranasal saline, and surgery, are
available. Even though the medical treatment is the
cornerstone in the AR management, the recurrence of
symptoms and development of adverse effects are common
problems due to the drug withdrawal. Therefore, treatment
modalities with improved safety profiles are required.
Mesenchymal stem cells (MSCs), multipotent progeni-
tor cells derived from the bone marrow, contribute to the
maintenance and regeneration of various connective tis-
sues, including bone, muscle, adipose, and cartilage [3, 4].
On the other hand, MSCs demonstrate their potent
immunomodulatory and anti-inflammatory effects in vari-
ous pulmonary conditions [5, 6] and decrease the tissue
damage and/or increase the repair in response to injury
upon migrating to the lung [7–9]. Therefore, in the previ-
ous studies, MSCs-derived bone marrow, adipose tissue,
and pluripotent stem cells were shown to attenuate allergic
responses in allergic airway diseases [6, 10–14].
The main aim of this study is to evaluate the migration
of bone marrow-derived mesenchymal stem cells
(BMSCs) to the nasal mucosa following their intraperi-
toneal delivery, the impact of BMSCs on nasal
histopathology, and Th2 immune responses in the murine
model of AR. Besides, we also aim to determine the
histopathological findings of chronic asthma, evaluate the
migration of BMCSs to the lung tissue, and, finally,
effects of BMSCs on the lung tissue in this particular
murine model of AR.
Materials and methods
Animals and experimental procedures
Conventionally raised, 6- to 8-week-old, 25 male BALB/c
mice (18–20 g) were used in the study. Mice were housed
in hygienic macrolen cages in the air conditioned room
with ad libitum access to food and water, and they were
exposed to a 12-h light/dark cycle. All experiments were
carried out according to the protocols approved by the local
animal use and care committee (Ethic committee number:
05/2012). In the study, procedures were applied in line with
the standard protocols of Guide for the Care and Use of
Laboratory Animals which were prepared by the Institute
of Laboratory Animal Resources and published by the
National Academy Press, National Research Council,
Commission of Life Sciences, and the Institute of Labo-
ratory Animal Resources.
BALB/c mice were chosen to establish the OVA-in-
duced mouse model of AR due to their good responses to
OVA [15]. After acclimatization of animals to the labora-
tory conditions, an AR model was established as previously
described [16]. Twenty-five BALB/c male mice
(7–8 weeks of age) were equally and randomly distributed
into five groups as following: group I (control group),
group II (sensitized and challenged with OVA and treated
with saline-placebo group), group III (sensitized and
challenged with OVA and treated with 1 9 106 BMSCs),
group IV (sensitized and challenged with OVA and treated
with 2 9 106 BMSCs), and group V (sensitized and chal-
lenged with PBS and treated with 1 9 106 BMSCs). Mice
in control group were not exposed to any treatment. In
groups II, III, and IV, mice were actively immunized
intraperitoneally with 10 lg of OVA, (Sigma Aldrich, St.
Louis, MS, USA) in 4 mg of aluminum hydroxide on Day
0 and Day 7. On Day 14, animals were intranasally chal-
lenged with 100-lg OVA in 10-ll phosphate-buffered
saline (PBS) twice a day for 1 week (totally 14 times in a
week) (Fig. 1). The immediate reactions of animals after
nasal challenge were examined according to AR
symptoms.
Evaluation of symptoms
AR was evaluated using some parameters, such as the
occurrence of typical clinical symptoms, such as eye and
nose irritation, conjunctival and nasal secretion, sneezing,
and the nasal acoustic phenomenon, reflecting the degree of
nasal obstruction. Symptom scores were graded on a four-
point scale. Each grade was assigned a numeric score
between 0 and 3; nasal symptom scores were graded as
follows: (a) sneeze: (0) none, (1) for 1–3/10 min, (2) for
4–9/10 min, and (3) for C10/10 min; (b) nasal itching
motion: (0) none, (1) rubbing nose for 2/min, (2) rubbing
nose for 4–6/min, and (3) rubbing nose for[6/min; and
(c) nasal mucus: (0) none, (1) in a nostril, (2) outside a
nostril, and (3) overflowing. Total score should be[5 to
achieve the successful AR model development [17, 18].
Isolation and cultivation of mesenchymal stem cells
from mouse bone marrow
Mouse mesenchymal stem cells (MSCs) were isolated from
the bone marrow aspirates obtained from tibia and femoral
parts of the compact bone [19]. The bones were kept in a
sterile petri dish, sterilized with 70 % ethanol and then
washed with 19 PBS at least two times. Then, the epi-
physes which were localized below the end of the marrow
cavity were removed using sterile scissors. A syringe
needle was inserted into the bone marrow cavity and the
marrow was completely flushed out with PBS until the
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bones became pale. The bone marrow suspension was
centrifuged at 1000 rpm for 10 min and the supernatant
was removed. The pellet was suspended and cultured in
Dulbecco’s modified Eagle’s medium (DMEM) (Invitro-
gen, Paisley, UK) containing 15 % fetal bovine serum
(FBS) and 1 % penicillin–streptomycin (37 C and 5 %
CO2 incubator) until BMSCs were attached. Then, non-
adherent cells were removed carefully and fresh medium
was supplied to cells. Cultured BMSCs were observed
under the microscope to control their expansion and mor-
phology. When primary cultures became 80–90 % conflu-
ent, cells were detached from culture flask surface using
Trypsin/EDTA solution and cells were seeded onto fresh
plates [20].
Transfection of MSCs with GFP
Cells were transfected with the pEGFP-N1 vector, includ-
ing green fluorescent protein (GFP), as the encoded
reported gene to track the MSCs in vivo. Lipid-based
transfection was performed using Metafectene Pro
transfection kit (Biontex, Martinsried/Planegg, Germany)
with some changes related to number of cells to seed and
plasmid DNA amount [21]. Briefly, 1 9 106 cells were
seeded onto 75-cm2 culture flask, including 12 ml of
complete medium the day before the transfection. Com-
plete medium was replaced with antibiotic- and serum free-
medium at the day of the transfection. Then, 6-lg GFP
plasmid was added into 20-ll Metafectene Pro transfec-
tion reagent and incubated at room temperature for 20 min
for the transfection-complex formation. After incubation,
GFP-lipid complexes were added dropwise to the adherent
cells and the culture flask was gently shaked. Then, cells
were incubated at 37 C in a 5 % CO2 incubator for 72 h
and the light density was obtained under fluorescence
microscope. The GFP-transfected cells were collected from
culture flask via trypsinization and counted upon trypan
blue staining. BMSCs were suspended in normal saline to
introduce them into allergic rhinitis animal models [20].
Characterization of BMSCs
The cells were incubated with antibodies against NG2 PE
(Beckman Coulter), CD45 PC5 (Beckman Coulter, Mar-
sillia, France), CD73 PE (Becton–Dickinson, Bioscience
Pharmingen, San Diego, CA, USA), and CD105 FITC
(Serotec, Oxford, UK). Fluorescence histograms were
obtained by recording 20,000 cells/sample at a flow rate of
approximately 200 cell events/s. Experiments were per-
formed using Coulter Epics XL-MCL and flow cytometric
data were analyzed using the EXPO 32 ADC software
(Beckman Coulter Inc, Miami, FL, USA) [22]. Flow
cytometric data analysis demonstrated that there were
significant expressions of MSC-specific antigens (CD105,
CD73, and NG2) and the absence of hematopoietic marker
antigen (CD45) [23].
BMSC and saline administration
Totally 1 9 106 and 2 9 106 BMSCs were administered to
mice via intraperitoneal injection into groups III and IV,
respectively. In group II (placebo group), only intraperi-
toneal saline was supplied.
Evaluation of nasal lavage fluid (NALF)
Nasal lavage fluid (NALF) was obtained upon the partial
tracheal resection using 22G catheters. The catheter was
inserted into the tracheal in the direction of the upper air-
way into the nasopharynx. The nasal passages were per-
fused with 1 ml of PBS from the choana to the nostril, and
NALF was collected from the nares.
Fig. 1 Timeline of the mouse
model of AR and treatment with
BMSCs and saline
Eur Arch Otorhinolaryngol (2017) 274:197–207 199
123
Histopathological analysis of nasal mucosa and lung
tissue
The mice were anesthetized with the overdose of ketamine
after 1 week upon the last BMSC administration. The lung
and the head of each mouse were removed and examined in
terms of histomorphological changes. Two investigators
who were blinded to the treatment groups interpreted the
histopathology results. Photomicrographs were taken by
Olympus DP25 camera (Japan), which was adapted on an
Olympus CX-41 model microscope (Olympus Optical,
Tokyo, Japan). The histological images were analyzed
using the image analyzer system (CellSens Entry).
Evaluation of nasal tissue
Mouse heads were fixed in 10 % buffered formalin and
decalcified in 10 % EDTA (pH 7.0) for 14 days. The tis-
sues were then embedded into paraffin and 5-lm coronal
sections of nasal cavity were obtained. Upon fixation,
samples were embedded into paraffin for light microscopic
evaluation. Paraffin sections of nasal mucosa were stained
with hematoxylin and eosin (H&E), periodic acid–Schiff
(PAS, for goblet cells), and May-Gru¨nwald stain (for
eosinophils). Epithelial thicknesses of the nasal septum
were measured at 409 magnification in H&E stained sec-
tions. Goblet cells in the nasal epithelium were counted and
the results were expressed as the number of goblet cells per
100-lm basal lamina. The numbers of eosinophils in the
nasal submucosa were counted and the results were
expressed as the number of eosinophils/mm of the basal
lamina. Histology of the nasal mucosa was evaluated with
respect to the epithelial disruption, loss of cilia, goblet cell
hyperplasia, and vascular congestion in the nasal mucosa.
The parameters were evaluated semi-quantitatively
(0 = no change, 1 = mild change, 2 = moderate change,
and 3 = severe change) [24, 25].
Evaluation of the lung tissue
Tissue specimens were obtained from the mid zone of the
left lung of mice. Lung tissue samples were immediately
fixed with 10 % buffered formalin and embedded into
paraffin for light microscopic evaluation, and serial sec-
tions of 5-lm thickness were prepared. For light micro-
scopic evaluation, three different staining processes were
used. The first 10 samples were stained with hematoxylin
and eosin (H&E). In these samples, general tissue features
were examined and thicknesses of the epithelium and
subepithelial smooth muscle layers of the medium and
small airways were measured. To evaluate the thicknesses
of epithelium and subepithelial smooth muscle layers, the
measurements were performed from 4 points of each
airway at the levels of 3, 6, 9, and 12 o’clock. The con-
secutive 10 sections were stained with toluidine blue and
the other 10 sections were stained with periodic acid Schiff
(PAS). Photomicrographs were taken randomly from 5
fields of each toluidine blue-stained sections. For mast cell
enumeration, a standard transparent counting frame repre-
senting an area of 16,400 lm2 was manually used, and 8
fields in each photograph were examined for each mouse.
Goblet cells which were stained with PAS were enumer-
ated in 10 sections of each mouse. In each section, ran-
domly selected 3-to-5 airways were photographed.
Diameters of all airways were measured and goblet cell
numbers were recorded. To analyze whether or not MSCs
migrated to the nasal and lung tissues, the confocal
microscopic evaluation was performed by a blinded
investigator.
Measurements of cytokine levels and differential cell
count in NALF
To evaluate Th2-mediated allergic reactions, IL-4, IL-5,
and IL-13 cytokine levels were measured in NALF super-
natants of each group using enzyme-linked immunosorbent
assay (eBioscience Mouse ELISA kit, USA).
Histological smear samples were prepared. The differ-
ential cell count was performed using May–Gru¨nwald–
Giemsa staining to classify cells as eosinophils, neu-
trophils, and lymphocytes on the basis of morphologic
criteria and staining characteristics. Differential cell counts
were performed in a blinded fashion by counting at least
200 cells per slide under the light microscope.
Measurement of lung nitric oxide (NO) levels
Nitric oxide levels were measured in supernatants obtained
from the lung tissue homogenizations (Invitrogen Griess
Reagent) using ELISA in accordance with the manufac-
turer’s recommendations. Griess Reagent (A: 1-naph-
thylethylene-diamine dihydrochloride, % 0.1; B: sulfanilic
acid, % 1) was added to samples with an equal volume in
microtiter plates (Greiner) and samples were stored at room
temperature for 30 min. Results were determined by
spectrophotometrically at 548 nm (BioTek Synergy HT,
USA) [26].
Statistical analysis
SPSS 15 package program was used for the statistical
analysis. Data were represented as mean ± standard devi-
ation (SD). The differences among all groups were com-
pared using the Kruskal–Wallis method. In case, there was
a significant difference between two groups, Mann–
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Whitney U test was used for pairwise group comparisons.
p\ 0.05 was considered as statistically significant.
Results
In the current study, histopathological results, cytokine
levels, and the migration of BMSCs to the nasal and lung
tissues of the groups were evaluated.
Characterization of mesenchymal stem cells
and evaluation of nasal and lung tissue migration
Flow cytometry analysis of the isolated cells from the bone
marrow demonstrated that there were significant expres-
sions of MSC-specific antigens (CD105, CD73, and NG2),
and no hematopoietic marker antigen (CD45) was detected
in any of the cell. While mice in group V did not have
significant BMSCs in their nasal and lung tissues, all mice
in group III and IV were shown to have green dots under
the confocal microscope indicating that labeled BMSCs
migrated to the inflamed nasal and lung tissues. DAPI
(40,6-diamidino-2-phenylindole) staining was used to
determine the number of nuclei and to assess gross cell
morphology (Fig. 2).
Evidence for establishment of AR murine model
To show the establishment of AR model, we compared the
symptomatic scores of AR model groups (groups II, III,
and IV) with groups I and V (Table 1; Fig. 3). Symp-
tomatic scores were significantly increased in groups II, III,
and IV compared to groups I and V. In group II (placebo),
number of goblet cells, eosinophils, and their histological
scores was significantly higher compared to the control
group. All of these results demonstrated that the AR murine
model was successfully established.
Results of histopathological analysis of the nasal
tissue
In group III, the number of goblet cells and eosinophils
was significantly lower, but the histological scores were
found to be similar when compared to the placebo
group. In group IV, all parameters (the number of goblet
cells, eosinophils, and histological scores) were signifi-
cantly lower compared to the placebo group (Table 2;
Figs. 4, 5).
Results of histopathological analysis of the lung
tissue
In addition to histological findings observed in lung tissues
of groups II, III, and IV, there were also histopathological
findings of chronic asthma in lung tissues of these groups.
In groups II, III, and IV, histological findings of chronic
asthma, such as the number of mast and goblet cells, and
epithelial and subepithelial smooth muscle layer thick-
nesses were significantly higher compared to the control
group. While only subepithelial smooth muscle layer
thicknesses and epithelium thicknesses were significantly
lower in group III, all of the histological parameters of
chronic asthma (the number of mast and goblet cells, and
epithelial and subepithelial smooth muscle layer thick-
nesses) were significantly lower in group IV compared to
the placebo group (Table 3; Figs. 6, 7a, b).
Fig. 2 Confocal microscopic
images of nasal and lung tissues
of groups II and IV (A1
confocal microscopic images of
nasal tissue and A2 confocal
microscopic images of lung
tissue of group II and B1
confocal microscopic images of
nasal tissue and B2 confocal
microscopic images of lung
tissue of group IV). DAPI 40,6-
diamidino-2-phenylindole, GFP
green fluorescent protein)
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Results of cytokine levels and differential cell count
in NALF
All of the cytokines (IL-4, IL-5, and IL-13) and NO levels
of the placebo group were significantly higher compared to
groups III and IV (Table 4; Fig. 8). In group IV, levels of
all cytokines and NO were significantly lower compared to
group III. The numbers of eosinophils in NALF were sig-
nificantly reduced in both groups receiving BMSCs when
compared to the placebo group. However, the percentage
of eosinophils was minimum in the control group and
maximum in the placebo group.
According to the all results, we have shown that at
higher dose of (2 9 106) BMSCs migrate to lung and nasal
tissues upon their intraperitoneal administration in the
murine model of AR and more effective than at lower dose
of (1 9 106) BMSCs on the remodeling and eosinophilic
inflammation in both upper and lower airways by sup-
pressing the Th2 immune response.
Discussion
Allergic rhinitis (AR) is the most common chronic condi-
tion in both adult and pediatric populations, affecting 10 to
30 % of adult and 20 to 40 % of children [1]. Presentation
of an allergen to lymphocytes leads to the Th2 cytokine
release, such as IL-4, IL-5, and IL-13, which promote IgE
production and the infiltration of the inflammatory cells,
such as eosinophils and mast cells to the mucosa. Even
though medical treatment is the cornerstone of AR man-
agement, the recurrence of symptoms and the development
of adverse effects are common problems due to the drug
withdrawal. Therefore, new and promising definitive
treatment options are required for AR.
Mesenchymal stem cells (MSCs) are multipotent pro-
genitor cells which were first identified in the bone
marrow and they have the ability to differentiate into
bone, fat, and cartilage [27]. In addition to their potential
for tissue repair, MSCs possess also potent anti-prolifer-
ative, anti-fibrotic, and anti-inflammatory and
immunomodulatory effects [28, 29] which can support
their therapeutic usage in immune-mediated diseases.
Their protective roles have been described in airway
diseases, such as acute lung injury [6], pulmonary fibrosis
[7], and, more recently, asthma [19] and allergic rhinitis
[13]. MSCs, in general, have established a very good
safety profile as validated through numerous clinical
studies. Multiple clinical studies have shown its safety in
the treatment of Crohn’s disease, steroid resistant graft
versus host disease, multiple sclerosis and amyotrophic
lateral sclerosis, chronic obstructive pulmonary disease,
and multiple other inflammatory and degenerative condi-
tions [30–33].
Fig. 3 Correlation graphics’ comparison of AR symptom scores of
study groups
Table 2 Histopathological findings of nasal tissue (mean ± SD)
Group I
(control)
(mean ± SD)
Group II
(placebo-AR?, saline)
(mean ± SD)
Group III
(AR?, 1 9 106 MSC)
(mean ± SD)
Group IV
(AR?, 2 9 106 MSC)
(mean ± SD)
Group V
(AR-, 1 9 106 MSC)
(mean ± SD)
Number of goblet cells/
l00 lm basal lamina
1.06 ± 0.15* 2.57 ± 0.39 1.32 ± 0.20* 0.92 ± 0.11* 0.94 ± 0.14*
Number of eosinophil/
mm basal lamina
2.63 ± 0.46* 6.81 ± 0.57 3.07 ± 0.39* 2.87 ± 0.44* 2.58 ± 0.51*
Histological scores 0.0 ± 0* 2.0 ± 0.31 1.0 ± 0.25 0.85 ± 0.26* 0.2 ± 0.2*
* p\ 0.05 in groups versus placebo (group II)
Table 1 Comparison of AR
symptom scores of study groups
(mean ± SD)
AR-positive groups
(groups II, III, IV) (mean ± SD)
AR-negative groups
(groups I and V) (mean ± SD)
p
Number of sneeze/10 min 18.6 ± 7.7 3.7 ± 2.2 0.00
Number of nasal rubbing/min 10.8 ± 10.7 1.7 ± 1.0 0.03
Nasal mucous 0.00 ± 0.00 0.00 ± 0.00 0.00
202 Eur Arch Otorhinolaryngol (2017) 274:197–207
123
Asthma is another disease closely related to AR. These
two pathologies: asthma and allergic rhinitis occur due to
similar pathogenic processes in different segments of air-
ways. However, it has recently been shown in literature
that these two diseases are associated with each other. The
presence of AR significantly predisposes to the develop-
ment of asthma later in life. Increased levels of inflam-
matory factors in the blood and propagation of the
inflammation through the airway or systemic pathways can
be possible mechanisms for lower airway dysfunction
among patients with upper airway diseases, such as AR.
When both diseases coexist, it is known that treating AR
can also lead to improvement in symptoms and severity of
asthma [34].
For the first time in this study, it has been shown that
BMSCs migrate to the nasal mucosa upon their intraperi-
toneal administration in murine model of AR. Furthermore,
it has also been indicated that BMCSs have positive effects
on histopathological findings, Th2 immune responses, and
NO levels.
In the present study, we have also observed various
histopathological findings of chronic asthma and migration
of BMSCs to the lung tissue of murine model of AR. We
have found that groups II, III, and IV mice have
histopathological findings of chronic asthma, such as
increased number of the mast and goblet cells, and
epithelial and subepithelial smooth muscle layer thick-
nesses in addition to histopathological findings of AR.
The immunoregulatory effects of MSCs are mainly
mediated through direct cell-to-cell interactions and para-
crine effects [35]. Thus, the recruitment of MSCs to the
sites of inflammation and injury is very important. The
optimal route for stem cell transplantation is another issue
which needs to be determined before its clinical applica-
tions. In contrast to a normal lung, an injured lung produces
soluble factors that induce MSCs proliferation and the
recruitment toward an injured lung [6]. Moreover, sys-
temically administered MSCs have been shown to localize
to an injured lung [36]. A recent study has also shown that
human MSCs which were administered by intraperitoneal
injection could be implanted into the lungs of newborn rats,
and they could effectively protect the rats against lung
Fig. 4 Light microscopic results of the groups belonging to the nasal
tissue. I Control, II placebo group, III AR developed and 1 9 106
BMSCs-treated group, IV AR developed and 2 9 106 BMSCs-treated
group, V non-AR and 1 9 106 BMSCs-treated group. In representa-
tive histological images, nasal tissues were stained with H&E (a; 1st
row), PAS (b; 2nd row), and May-Gru¨nwald (c; 3rd row). In placebo
group, H&E staining revealed increased cell size, vascular conges-
tion, and epithelial damage (a II), PAS staining revealed goblet cell
hyperplasia in the respiratory epithelium overlying nasal septum
(black arrows, b II) and high number of eosinophil were seen with
May–Gru¨nwald staining (black arrow, c III). In the group III, IV,
pathological changes, goblet cell hyperplasia, and numbers of
eosinophils were significantly less compared to the placebo group
(b IV, c IV). Histological scores of nasal mucosa, including epithelial
disruption, loss of cilia, goblet cell hyperplasia, chondrocyte hyper-
trophy, and vascular congestion, were significantly decreased in group
IV compared to the placebo group, and there were no differences
between group III and the placebo group
Fig. 5 Correlation graphics’ histopathological findings of nasal
tissues
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damage to due to the hyperoxia [37]. In this study, it was
primarily shown that BMSCs migrated into both nasal and
lung tissues of group III and IV mice following an
intraperitoneal delivery of BMSCs.
Allergic rhinitis (AR) and asthma are characterized by
skewed Th2 cells, eosinophilic inflammation, mucus
hypersecretion, and airway hyperresponsiveness [1]. The
excessive activation of Th2 cells is thought to play a major
role in the initiation of clinical features, including allergic
sensitization and driving airway hyperresponsiveness [38].
Few published reports evaluating effects of MSCs on CD4
T lymphocyte differentiation generally demonstrate that
MSCs tend to shift CD4 T lymphocytes toward a Th2
phenotype both in vitro and in vivo [39, 40]. These findings
suggest that administration of MSCs might be either inef-
fective or can potentially exacerbate immune responses in a
model of Th2-mediated inflammation, such as allergic
asthma. However, there are lots of opposed studies in the
literature in this field.
In our study, it was observed in group III and group IV
(BMCSs administered groups) that eosinophilic inflam-
mation in both nasal and lung tissues and IL-4, IL-5, and
IL-13 cytokine levels (signs of Th2 immune response in
BAL fluid) were suppressed. In a recent study, in which a
mouse model of OVA-induced Th2-mediated eosinophilic
allergic airways inflammation was used, authors found that
systemic administration of either syngeneic or allogeneic
BMSCs during the antigen sensitization process inhibited
both airways hyperreactivity and lung inflammation
through a mechanism partly dependent on IFN-gamma
[41]. Syngeneic adipose-derived MSCs (ASCs) were also
shown to inhibit both OVA-induced allergic rhinitis and
Fig. 6 Light microscopic findings of the groups belonging to the lung
tissue. I Control, II placebo group, III AR developed and 1 9 106
BMSCs-treated group, IV AR developed and 2 9 106 BMSCs-treated
group, V non-AR, 1 9 106 BMSCs-treated group. In representative
histological images, lung tissues were stained with H&E (a; 1st row),
PAS (b; 2nd row), Toluidin blue (c; 3rd row), and electron
microscopic views (d; 4th). In control group, light microscopic
findings revealed a regular, normal bronchiole wall thickness,
bronchiole lumen (a I). In placebo group, H&E staining (a II)
revealed thickened epithelium, thickened subepithelial smooth muscle
(arrow with two heads), and peribronchial mononuclear infiltration
(asterisk). High numbers of goblet cells were seen with PAS staining
(b II) (arrow with one head), and mast cells with toluidine blue
staining (c II) (arrow with one head). Only in group IV, all of the
histological parameters (epithelium thickness, subepithelial smooth
muscle thickness, number of goblet, and mast cells) have improved
compared to the placebo group (black arrow). In group III, epithelium
thickness and subepithelial smooth muscle thickness were signif-
icantly less than the placebo group, and no statistical difference was
found in the number of goblet and mast cells (b III, c III) between
both groups
Table 3 Histopathological findings of lung tissue (mean ± SD)
Group 1
(control)
(mean ± SD)
Group II
(placebo-AR?, saline)
(mean ± SD)
Group III
(AR?, 1 9 106 MSC)
(mean ± SD)
Group IV
(AR?, 2 9 106 MSC)
(mean ± SD)
Group V
(AR-, 1 9 106 MSC)
(mean ± SD)
Epithelium thickness
(lm)
011.39 ± 0.63* 15.18 ± 0.54 11.94 ± 0.39* 12.21 ± 0.35* 12.69 ± 0.65*
Number of goblet cells/
l00 lm
0.24 ± 0.07* 2.31 ± 0.39 1.26 ± 0.34 0.74 ± 0.20* 0.77 ± 0.24*
Subepithelial smooth
muscle thickness (lm)
5.82 ± 0.14* 10.21 ± 0.33 6.41 ± 0.35* 6.45 ± 0.37* 5.9 ± 0.38*
Number of mast cells/
20,000 lm2
0.27 ± 0.11* 1.31 ± 0.32 0.67 ± 0.13* 0.54 ± 0.10* 0.49 ± 0.13*
* p\ 0.05 in groups versus placebo (group II)
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allergic airways inflammation when administered during or
before the antigen challenge in previously sensitized mice.
ASCs appeared to promote Th1 activation as measured by
IFN-gamma levels in the BAL fluid. Besides, polyclonally
activated CD4 T lymphocytes were recovered from BAL
and spleen and they were stained positively for intracellular
IFN-gamma [42]. In another study, the immunomodulatory
effects of mesenchymal stem cells derived from human-
induced pluripotent stem cells (iPSC-MSCs) and BMSCs
on lymphocyte proliferation, T-cell phenotypes and cyto-
kine production in peripheral blood mononuclear cells
were compared in patients with AR. Conclusively, the
possible molecular mechanisms underlying the
immunomodulatory properties of iPSC-MSCs were shown.
Accordingly, authors demonstrated that iPSC-MSCs were
capable of modulating T-cell phenotypes towards Th2
suppression by inducing the Treg expansion [43]. Abreu
et al. compared the effects of bone marrow-derived
mononuclear cells (BMMCs) and mesenchymal stromal
cells (MSCs) on airway inflammation and remodeling and
lung mechanics in an experimental allergic asthma model.
They demonstrated that both BMMCs and MSC adminis-
tration decreased the cell infiltration, bronchoconstriction
index, alveolar collapse, collagen fiber content in the
alveolar septa, interleukin IL-4, IL-13, transforming
growth factor (TGF), and vascular endothelial growth
factor (VEGF) levels compared to placebo samples [44].
Another study showed that human MSCs administered
upon the induction of airway disease dramatically
decreased the pathology and airway inflammation associ-
ated with the OVA albumin model of chronic asthma,
which may be related to the modulation of IL-5, IL-13,
IgE, and inducible nitric oxide synthase (INOS) expression
[11]. In our study, Th2 cytokines and number of eosino-
phils in NALF fluid and NO levels of BMSC-treated
groups (groups III and IV) were significantly lower com-
pared to the placebo group. Furthermore, similar to the
study of Bonfield et al., BMSCs administration in both
groups (groups III and IV) improved the nasal and lung
histopathology of diseases, such as AR and asthma.
Administration of BMSCs to group V mice was well
Fig. 7 a, b Correlation graphics’ histopathological findings of lung
tissues
Fig. 8 Correlation graphics’ cytokine levels in nasal lavage fluid and
lung homogenants
Table 4 Cytokine levels in nasal lavage fluid and lung homogenants (mean ± SD)
Group I
(control)
(mean ± SD)
Group II (placebo-
AR?, saline)
(mean ± SD)
Group III (AR?,
l 9 106 MSC)
(mean ± SD)
Group IV (AR?,
2 9 106 MSC)
(mean ± SD)
Group V (AR-,
1 9 106 MSC)
(mean ± SD)
IL-4 (pg/ml) (NALF) 0.056 ± 0.040* 0.478 ± 0.045 0.141 ± 0.031* 0.230 ± 0.031* 0.135 ± 0.029*
IL-S (pg/ml) (NALF) 0.069 ± 0.024* 0.424 ± 0.056 0.115 ± 0.043* 0.220 ± 0.045* 0.123 ± 0.014*
IL-13 (pg/ml) (NALF) 0.076 ± 0.028* 0.436 ± 0.052 0.123 ± 0.025* 0.220 ± 0.063* 0.140 ± 0.042*
No (lM) (lung
homogenants)
0.067 ± 0.041* 0.486 ± 0.068 0.140 ± 0.065* 0.240 ± 0.032* 0.139 ± 0.049*
* p\ 0.05 in groups versus placebo (group II)
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tolerated and it did not affect any of measurements of nasal
and lung inflammation or levels of Th2 cytokines and NO
compared to control mice. This is an important observation
which highlights a specific immunomodulatory role of
BMSCs only under conditions of immune stimulation or
disruption. Conclusively, it is shown in this study that
BMSCs migrate to lung and nasal tissues upon their
intraperitoneal administration in the murine model of AR
and ameliorate the remodeling and eosinophilic inflam-
mation in both upper and lower airways by suppressing the
Th2 immune response. The present data are compatible
with the previous studies which were performed on the
MSCs treatment for allergic airway inflammation. Further
research is needed to assess the favorable effects of BMSC
therapy in these aspects in human asthma and AR.
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